Étienne Gaudette1, Dana P Goldman, Andrew Messali, Neeraj Sood. 1. Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, 635 Downey Way, Suite 210, Los Angeles, California, 90089-3333, USA, egaudett@healthpolicy.usc.edu.
Abstract
CONTEXT: Obesity impacts both individual health and, given its high prevalence, total health care spending. However, as medical technology evolves, health outcomes for a number of obesity-related illnesses improve. This article examines whether medical innovation can mitigate the adverse health and spending associated with obesity, using statins as a case study. Because of the relationship between obesity and hypercholesterolaemia, statins play an important role in the medical management of obese individuals and the prevention of costly obesity-related sequelae. METHODS: Using well-recognized estimates of the health impact of statins and the Future Elderly Model (FEM)-an established dynamic microsimulation model of the health of Americans aged over 50 years-we estimate the changes in life expectancy, functional status and health care costs of obesity due to the introduction and widespread use of statins. RESULTS: Life expectancy gains of statins are estimated to be 5-6 % greater for obese individuals than for healthy-weight individuals, but most of these additional gains are associated with some level of disability. Considering both medical spending and the value of quality-adjusted life-years, statins do not significantly alter the costs of class 1 and 2 obesity (body mass index [BMI] ≥30 and ≥35 kg/m(2), respectively) and they increase the costs of class 3 obesity (BMI ≥40 kg/m(2)) by 1.2 %. CONCLUSIONS: Although statins are very effective medications for lowering the risk of obesity-associated illnesses, they do not significantly reduce the costs of obesity.
CONTEXT: Obesity impacts both individual health and, given its high prevalence, total health care spending. However, as medical technology evolves, health outcomes for a number of obesity-related illnesses improve. This article examines whether medical innovation can mitigate the adverse health and spending associated with obesity, using statins as a case study. Because of the relationship between obesity and hypercholesterolaemia, statins play an important role in the medical management of obese individuals and the prevention of costly obesity-related sequelae. METHODS: Using well-recognized estimates of the health impact of statins and the Future Elderly Model (FEM)-an established dynamic microsimulation model of the health of Americans aged over 50 years-we estimate the changes in life expectancy, functional status and health care costs of obesity due to the introduction and widespread use of statins. RESULTS: Life expectancy gains of statins are estimated to be 5-6 % greater for obese individuals than for healthy-weight individuals, but most of these additional gains are associated with some level of disability. Considering both medical spending and the value of quality-adjusted life-years, statins do not significantly alter the costs of class 1 and 2 obesity (body mass index [BMI] ≥30 and ≥35 kg/m(2), respectively) and they increase the costs of class 3 obesity (BMI ≥40 kg/m(2)) by 1.2 %. CONCLUSIONS: Although statins are very effective medications for lowering the risk of obesity-associated illnesses, they do not significantly reduce the costs of obesity.
Authors: Dana P Goldman; Yuhui Zheng; Federico Girosi; Pierre-Carl Michaud; S Jay Olshansky; David Cutler; John W Rowe Journal: Am J Public Health Date: 2009-09-17 Impact factor: 9.308
Authors: Seth A Seabury; Sarah Axeen; Gwyn Pauley; Bryan Tysinger; Danielle Schlosser; John B Hernandez; Hanke Heun-Johnson; Henu Zhao; Dana P Goldman Journal: Health Aff (Millwood) Date: 2019-04 Impact factor: 6.301
Authors: Yunan Han; Chee Teik Lee; Shuai Xu; Xiaoyue Mi; Courtnie R Phillip; Ana S Salazar; Malika Rakhmankulova; Adetunji T Toriola Journal: Breast Cancer Res Treat Date: 2021-07-01 Impact factor: 4.624